Blueprint Medicines Co. to Post Q1 2025 Earnings of ($0.93) Per Share, Wedbush Forecasts (NASDAQ:BPMC)

Blueprint Medicines Co. (NASDAQ:BPMC) – Wedbush issued their Q1 2025 earnings estimates for shares of Blueprint Medicines in a research note issued on Thursday, May 2nd. Wedbush analyst D. Nierengarten anticipates that the biotechnology company will post earnings of ($0.93) per share for the quarter. Wedbush currently has a “Outperform” rating and a $110.00 target price on the stock. The consensus estimate for Blueprint Medicines’ current full-year earnings is ($5.38) per share. Wedbush also issued estimates for Blueprint Medicines’ Q2 2025 earnings at ($0.75) EPS, Q3 2025 earnings at ($0.61) EPS and Q4 2025 earnings at ($0.43) EPS.

BPMC has been the subject of a number of other research reports. The Goldman Sachs Group boosted their price target on shares of Blueprint Medicines from $121.00 to $168.00 and gave the stock a “buy” rating in a research note on Monday. JMP Securities increased their target price on Blueprint Medicines from $114.00 to $125.00 and gave the company a “market outperform” rating in a research note on Friday, May 3rd. Stifel Nicolaus lifted their price target on Blueprint Medicines from $120.00 to $130.00 and gave the stock a “buy” rating in a research note on Friday, April 26th. StockNews.com upgraded Blueprint Medicines from a “sell” rating to a “hold” rating in a research report on Friday, May 3rd. Finally, Piper Sandler boosted their target price on Blueprint Medicines from $78.00 to $104.00 and gave the stock a “neutral” rating in a research report on Friday, May 3rd. Two equities research analysts have rated the stock with a sell rating, six have issued a hold rating, eight have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $100.31.

Blueprint Medicines Stock Up 2.2 %

BPMC stock opened at $108.55 on Monday. The company’s 50 day moving average is $92.17 and its 200 day moving average is $81.81. The stock has a market cap of $6.64 billion, a price-to-earnings ratio of -22.57 and a beta of 0.65. The company has a current ratio of 3.76, a quick ratio of 3.61 and a debt-to-equity ratio of 0.67. Blueprint Medicines has a 1-year low of $43.89 and a 1-year high of $110.93.

Blueprint Medicines (NASDAQ:BPMC) last posted its earnings results on Thursday, February 15th. The biotechnology company reported ($1.82) EPS for the quarter, topping the consensus estimate of ($2.04) by $0.22. The business had revenue of $71.96 million during the quarter, compared to analysts’ expectations of $67.34 million. Blueprint Medicines had a negative return on equity of 193.48% and a negative net margin of 102.15%. The firm’s revenue was up 85.5% on a year-over-year basis. During the same period in the previous year, the business earned ($2.65) earnings per share.

Hedge Funds Weigh In On Blueprint Medicines

Several hedge funds have recently made changes to their positions in BPMC. Sei Investments Co. lifted its stake in Blueprint Medicines by 36.6% in the first quarter. Sei Investments Co. now owns 45,913 shares of the biotechnology company’s stock worth $4,355,000 after acquiring an additional 12,311 shares during the period. Susquehanna Fundamental Investments LLC purchased a new stake in shares of Blueprint Medicines in the 1st quarter worth about $474,000. Swiss National Bank boosted its stake in shares of Blueprint Medicines by 0.4% during the 1st quarter. Swiss National Bank now owns 114,000 shares of the biotechnology company’s stock valued at $10,814,000 after purchasing an additional 500 shares in the last quarter. SG Americas Securities LLC increased its position in shares of Blueprint Medicines by 117.6% during the first quarter. SG Americas Securities LLC now owns 11,865 shares of the biotechnology company’s stock valued at $1,126,000 after buying an additional 6,412 shares during the period. Finally, Allspring Global Investments Holdings LLC bought a new position in Blueprint Medicines in the first quarter worth about $218,000.

Insider Activity

In related news, Director Jeffrey W. Albers sold 25,073 shares of Blueprint Medicines stock in a transaction on Wednesday, March 20th. The shares were sold at an average price of $87.28, for a total value of $2,188,371.44. Following the transaction, the director now directly owns 176,050 shares of the company’s stock, valued at $15,365,644. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. In other Blueprint Medicines news, Director Jeffrey W. Albers sold 25,073 shares of the stock in a transaction on Wednesday, March 20th. The shares were sold at an average price of $87.28, for a total transaction of $2,188,371.44. Following the completion of the sale, the director now owns 176,050 shares of the company’s stock, valued at approximately $15,365,644. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CFO Michael Landsittel sold 13,734 shares of the business’s stock in a transaction dated Friday, March 15th. The shares were sold at an average price of $87.78, for a total transaction of $1,205,570.52. Following the completion of the transaction, the chief financial officer now owns 47,286 shares in the company, valued at approximately $4,150,765.08. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 104,123 shares of company stock valued at $9,554,679. 3.88% of the stock is currently owned by company insiders.

About Blueprint Medicines

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.